Yandong Gong

Yandong Gong

Auto-generated profile, based on publicly available information

Yandong Gong

State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Senior Department of Hematology, Fifth Medical Center, Medical Innovation Research Department, Chinese PLA General Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Science Advances
Verified
Journal Article
Closed access
CLChao Liu
Chao Liu
MZMin Zhang
Min Zhang
XYXinlong Yan
Xinlong Yan
YNYanli Ni
Yanli Ni
YGYandong Gong
Yandong Gong
JYJinming Yu
Jinming Yu
Cervical squamous cell carcinoma (CESC) is a prototypical human cancer with well-characterized pathological stages of initiation and progression. However, high-resolution knowledge of the transcriptional programs underlying each stage of CESC is lacking, and important questions remain. We performed single-cell RNA sequencing of 76,911 individual cells from 13 samples of human cervical tissues at various stages of malignancy, illuminating the transcriptional tumorigenic trajectory of cervical epithelial cells and revealing key factors involved in CESC initiation and progression. In addition, we found significant correlations between the abundance of specific myeloid, lymphoid, and endothelial cell populations and the progression of CESC, which were also associated with patients’ prognosis. Last, we demonstrated the tumor-promoting function of matrix cancer–associated fibroblasts via the NRG1-ERBB3 pathway in CESC. This study provides a valuable resource and deeper insights into CESC initiation and progression, which is helpful in refining CESC diagnosis and for the design of optimal treatment strategies.

23 May 2023 in Journal of Genetics and Genomics
Verified
Journal Article
Open access
XNXiaowei Ning
Xiaowei Ning
JDJunjie Du
Junjie Du
YGYandong Gong
Yandong Gong
YYYingpeng Yao
Yingpeng Yao
ZBZhijie Bai
Zhijie Bai
SHSiyuan Hou
Siyuan Hou
Prior to the generation of hematopoietic stem cells (HSCs) from the hemogenic endothelial cells (HECs) mainly in the dorsal aorta in midgestational mouse embryos, multiple hematopoietic progenitors including erythro-myeloid progenitors (EMPs) and lymphoid progenitors are generated from yolk sac HECs. These HSC-independent hematopoietic progenitors have recently been identified as major contributors to functional blood cell production until birth. However, little is known about yolk sac HECs. Here, combining integrative analyses of multiple single-cell RNA-sequencing datasets and functional assays, we reveal that Neurl3-EGFP, in addition to marking the continuum throughout the ontogeny of HSCs from HECs, can also serve as a single enrichment marker for yolk sac HECs. Moreover, while yolk sac HECs have much weaker arterial characteristics compared to either arterial endothelial cells in the yolk sac or HECs within the embryo proper, the lymphoid potential of yolk sac HECs is largely confined to the arterial-biased subpopulation featured by the Unc5b expression. Interestingly, the B-lymphoid potential of hematopoietic progenitors, but not for myeloid potentials, is exclusively detected in Neurl3-negative subpopulations in midgestational embryos. Taken together, these findings enhance our understanding of blood birth from yolk sac HECs and provide theoretical basis and candidate reporters for monitoring step-wise hematopoietic differentiation.

24 June 2026 in Nature
Verified
Journal Article
Closed access
PDF file
ZXZhenyu Xiao
Zhenyu Xiao
YGYandong Gong
Yandong Gong
XYXiaolong Yang
Xiaolong Yang
NHNannan He
Nannan He
XWXinyuan Wang
Xinyuan Wang
YLYu Lan
Yu Lan

25 August 2025
Verified
Preprint
Open access
SZShuomin Zhang
Shuomin Zhang
QFQingfeng Fu
Qingfeng Fu
XYXiaotong Yuan
Xiaotong Yuan
SWSijun Wang
Sijun Wang
CLChao Liu
Chao Liu
GYGong Yandong
Gong Yandong
Colorectal cancer (CRC) remains a significant global health challenge, ranking among the leading causes of cancer-related morbidity and mortality. The tumor microenvironment (TME)—comprising immune cells, stromal elements, and extracellular matrix—plays a pivotal role in tumorigenesis, progression, and therapeutic resistance. Recent advancements in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) have revolutionized our understanding of the CRC TME by allowing high-resolution profiling of cellular heterogeneity and spatial dynamics. These cutting-edge technologies have uncovered novel, previously uncharacterized subsets of immune and stromal cells, all of which significantly relate to immune evasion and malignant progression. This review consolidates recent insights from single-cell and spatial transcriptomic studies, emphasizing the identification of novel cellular subtypes and their roles in modulating the TME. We also discuss the therapeutic implications of these findings, particularly in the development of targeted immunotherapies and combinatorial strategies aimed at improving clinical outcomes for CRC patients. By deepening our understanding of this complex cellular ecosystem, these insights are expected to inform more precise and effective therapeutic approaches for CRC.